Pharmacodynamics of Injection of Cisatracurium Base on Lean Body Mass Pattern to Maintain Deep Neuromuscular Blockade in Obese Patients

The First Hospital of Qinhuangdao

Status: Completed

Conditions: Obese Patients; Laparoscopic Colorectal Surgery

Treatments: Behavioral: base on Actual Body Weight; Behavioral: base on Lean Body Mass Pattern; Genetic: normal patients; Genetic: obese patients

Study type: Interventional

Funder types: Other

Identifiers

NCT05391958

070733

Details and patient eligibility

About

To observe the pharmacodynamics of intravenous injection of cisatracurium to maintain deep neuromuscular blockade in obese patients with lean body mass in laparoscopic colorectal surgery

Full description

According to the random number table method, one hundred and twenty patients who underwent elective laparoscopic colorectal surgery were divided into four groups (n=30): Normal weight patients according to lean body weight group(NL group), normal weight patients according to real weight group (NR group), obese patients according to lean body weight group(OL group), and obese patients according to real weight group(OR group).Intraoperative deep neuromuscular blockade (PTC≤2)was maintained in all four groups.The dosage of cisatracurium, the number of injections,time to effect,time to recovery from TOFr,time to recover TOFr（train-of-four rate） to 0.7 and 0.9,and time to stay in PCAU were recorded.The surgeon's satisfaction with the operative field and the average intraoperative pneumoperitoneum pressure were recorded at the time of pneumoperitoneum establishment,1 hour and 2 hours after pneumoperitoneum establishment.

Enrollment: 120 patients

Sex: All

Ages: 18 to 65 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Laparoscopic Colorectal Surgery
• American Society of Anesthesiologists (ASA) grades I-III

Exclusion criteria

• Patients with heart, lung and other vital organ disorders
• Preoperative fluid and electrolyte disturbance
• Preoperative water and electrolyte disorders have a history of neuromuscular disease or take medications that have an impact on neuromuscular function
• There is a significant airway difficulty
• Refuse to sign informed consent

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: Double Blind

---

120 participants in 4 patient groups

Normal Real group

Sham Comparator group

Description:

the medication group was given according to the actual weight of normal weight patients

Treatment:

Behavioral: base on Actual Body Weight

Genetic: normal patients

Normal Lean group

Active Comparator group

Description:

For normal weight patients, the medication group was given according to the lean body mass

Treatment:

Genetic: normal patients

Behavioral: base on Lean Body Mass Pattern

Obese Real group

Sham Comparator group

Description:

the medication group was given according to the actual weight of obese weight patients

Treatment:

Genetic: obese patients

Behavioral: base on Actual Body Weight

Obese Lean group

Experimental group

Description:

the medication group was given according to the lean body mass of obese weight patients

Treatment:

Genetic: obese patients

Behavioral: base on Lean Body Mass Pattern